Literature DB >> 33791165

Aptamer-guided targeting of the intracellular long-noncoding RNA HOTAIR.

Yuan-Liang Wang1,2, Ling-Chu Chang3, Kuen-Bao Chen2,4, Shao-Chun Wang1,2,5,6,7,8.   

Abstract

Long non-coding RNAs (lncRNAs) are increasingly recognized as promising targets in cancer treatment. However, compared to targeting the ordinary protein-coding genes, suppressing non-coding RNAs expressed in cancer cells has been a more challenging task. The major hurdles lay on the requirement of a tumor-specific delivery system for the designated inhibitor to suppress the target transcripts within the cellular compartment. EGFR is a cancer driver gene which is frequently associated with the triple-negative phenotype of breast cancer. Prior studies have shown that expression of the tumor-promoting lncRNA HOTAIR (HOX antisense intergenic RNA) is positively regulated by the epithelial growth factor receptor (EGFR) in triple-negative breast cancer (TNBC), and consistently the expression of both genes is closely correlated in breast cancer. Here we show that a chimeric aptamer recognizing the epithelial growth factor receptor (EGFR) coupled with a siRNA against HOTAIR (EGFR aptamer-coupled siHOTAIR) preferentially and effectively down-regulated HOTAIR in EGFR-expressing cancer cells. Functionally, the EGFR aptamer-coupled siHOTAIR more potently inhibited the growth, migration, and invasion of EGFR-expressing TNBC cells as well as cells with reconstituted EGFR compared to cancer cells with low EGFR expression. Our results demonstrate a novel strategy of targeting cancer progression by aptamer-directed delivery of anti-lncRNA RNA interference that can be applicable to other cellular contexts and cancer types. AJCR
Copyright © 2021.

Entities:  

Keywords:  EGFR; HOTAIR; TNBC; aptamer; long non-coding RNA; receptor tyrosine kinase; siRNA; triple-negative breast cancer

Year:  2021        PMID: 33791165      PMCID: PMC7994153     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  33 in total

1.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Authors:  Lisa A Carey; Hope S Rugo; P Kelly Marcom; Erica L Mayer; Francisco J Esteva; Cynthia X Ma; Minetta C Liu; Anna Maria Storniolo; Mothaffar F Rimawi; Andres Forero-Torres; Antonio C Wolff; Timothy J Hobday; Anastasia Ivanova; Wing-Keung Chiu; Madlyn Ferraro; Emily Burrows; Philip S Bernard; Katherine A Hoadley; Charles M Perou; Eric P Winer
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  The discovery of receptor tyrosine kinases: targets for cancer therapy.

Authors:  Andreas Gschwind; Oliver M Fischer; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

Review 3.  Long noncoding RNAs and human disease.

Authors:  Orly Wapinski; Howard Y Chang
Journal:  Trends Cell Biol       Date:  2011-05-06       Impact factor: 20.808

4.  Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

Authors:  Katie M O'Brien; Stephen R Cole; Chiu-Kit Tse; Charles M Perou; Lisa A Carey; William D Foulkes; Lynn G Dressler; Joseph Geradts; Robert C Millikan
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

Review 5.  Role of epidermal growth factor receptor in breast cancer.

Authors:  Hiroko Masuda; Dongwei Zhang; Chandra Bartholomeusz; Hiroyoshi Doihara; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2012-10-17       Impact factor: 4.872

6.  MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR.

Authors:  Rong Wang; Xiaofeng Chen; Tongpeng Xu; Rui Xia; Liang Han; Wenming Chen; Wei De; Yongqian Shu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

7.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Authors:  Leonie Voorwerk; Maarten Slagter; Hugo M Horlings; Karolina Sikorska; Koen K van de Vijver; Michiel de Maaker; Iris Nederlof; Roelof J C Kluin; Sarah Warren; SuFey Ong; Terry G Wiersma; Nicola S Russell; Ferry Lalezari; Philip C Schouten; Noor A M Bakker; Steven L C Ketelaars; Dennis Peters; Charlotte A H Lange; Erik van Werkhoven; Harm van Tinteren; Ingrid A M Mandjes; Inge Kemper; Suzanne Onderwater; Myriam Chalabi; Sofie Wilgenhof; John B A G Haanen; Roberto Salgado; Karin E de Visser; Gabe S Sonke; Lodewyk F A Wessels; Sabine C Linn; Ton N Schumacher; Christian U Blank; Marleen Kok
Journal:  Nat Med       Date:  2019-05-13       Impact factor: 53.440

8.  Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.

Authors:  Yuan-Liang Wang; Anne-Marie Overstreet; Min-Shan Chen; Jiang Wang; Hua-Jun Zhao; Po-Chun Ho; Molly Smith; Shao-Chun Wang
Journal:  Oncotarget       Date:  2015-05-10

9.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

10.  Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Authors:  Luc Y Dirix; Istvan Takacs; Guy Jerusalem; Petros Nikolinakos; Hendrik-Tobias Arkenau; Andres Forero-Torres; Ralph Boccia; Marc E Lippman; Robert Somer; Martin Smakal; Leisha A Emens; Borys Hrinczenko; William Edenfield; Jayne Gurtler; Anja von Heydebreck; Hans Juergen Grote; Kevin Chin; Erika P Hamilton
Journal:  Breast Cancer Res Treat       Date:  2017-10-23       Impact factor: 4.872

View more
  1 in total

Review 1.  Long Non Coding RNA Based Regulation of Cerebrovascular Endothelium.

Authors:  Samatha Mathew; Sridhar Sivasubbu
Journal:  Front Genet       Date:  2022-04-13       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.